揭示差异性DNA甲基化在胰腺导管腺癌中的临床影响:一项系统综述
该系统综述注册于PROSPERO(CRD42023451955)并遵循PRISMA指南,检索多个数据库,最终纳入19项研究,评估基因或CpG位点甲基化对胰腺导管腺癌诊断、预后或生存的影响。结论认为PDAC与一系列表观遗传修饰相关,特定基因甲基化可能影响生存和预后并成为治疗靶点,个体化表观遗传分析可能是未来方向。
要点
- SFRP1髙甲基化与PDAC不良预后相关(n=3/19,15.7%)。
- 个体化表观遗传分析可能是未来指导PDAC治疗和预后的方向。
核心结论
- PDAC与一系列表观遗传修饰相关,特定基因甲基化可能影响生存和预后并成为治疗靶点,个体化表观遗传分析可能是未来方向。
研究设计与样本
- 系统综述,注册于PROSPERO(CRD42023451955),遵循PRISMA指南,检索CINAHL Plus、Cochrane Library、Embase、Web of Science、Ovid Medline和Google Scholar,最终纳入19项研究。
主要发现
- 初始检索获得2402篇文章,排除423篇重复文献,应用排除标准后纳入19项研究。
- 研究提示SFRP1和NPTX2的髙甲基化与不良预后相关。
关键数值与推荐
- 纳入标准包括诊断为PDAC的患者以及可能影响PDAC诊断、预后或生存的基因或CpG位点信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite significant efforts to improve clinical outcomes, pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate. The poor prognosis associated with this disease is multifactorial and associated with a highly variable genetic profile associated with its pathogenesis. Epigenetic modifications including DNA methylation further affect the expression of genetic material. However, there is no comprehensive understanding of the clinical impact of DNA methylation in PDAC. METHODS: A systematic literature review was registered on the International Prospective Register of Systematic Reviews database (CRD42023451955) and followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. An electronic search was conducted using the following databases: CINAHL Plus, Cochrane Library, Embase, Web of Science, Ovid Medline, and Google Scholar. Inclusion criteria included studies of patients with a PDAC diagnosis and information regarding genes or CpG sites that potentially affect diagnosis, prognosis, or survival of PDAC. RESULTS: The initial search retrieved 2402 articles, and 423 duplicates were excluded. After exclusion criteria was applied, 19 studies were included. The most common genes recorded as affecting tumor pathogenesis were SFRP1 (n = 3/19, 15.7 %) and NPTX2 (n = 2/19, 10,5 %). Studies indicated that hypermethylation of SFRP1 and NPTX2 were associated with poor prognosis. CONCLUSIONS: PDAC is associated with a range of epigenetic modifications. Methylation of specific genes related to PDAC may influence survival and prognosis and be a therapeutic target. Individual patient epigenetic analysis may be a future direction in directing PDAC treatment and prognosis.
引用
- Kasmirski JA, Roy R, Wu C, et al. Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review. Eur J Cancer. 2025. PMID: 40154213. doi:10.1016/j.ejca.2025.115384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。